Page 103 - 《中国药房》2024年12期
P. 103

基于海南省特许药品监测系统和FAERS的氟轻松玻璃体植入剂

          的风险信号挖掘
                                   Δ


                                           4
                          2 #
                 1*
          苗会青 ,林 凯 ,姚明宏 ,林丽君(1.海南省药物警戒中心,海口 570216;2.海南省药品和医疗器械审评服
                                   3
          务中心,海口 570216;3.四川大学华西医院中国循证医学中心,成都 610041;4.海口市药物警戒中心,海口
          570100)

          中图分类号  R979.5      文献标志码  A      文章编号  1001-0408(2024)12-1505-06
          DOI  10.6039/j.issn.1001-0408.2024.12.16

          摘  要  目的  挖掘氟轻松玻璃体植入剂的风险信号,促进患者安全合理用药。方法  基于海南省特许药品不良反应监测子系统
         (以下简称“特许药品监测系统”)数据及FDA不良事件报告系统(FAERS)数据,采用系统器官分类及首选术语对氟轻松玻璃体植
          入剂的药品不良反应(ADR)/不良事件(ADE)报告进行编码,统计相关患者的信息,采用报告比值比(ROR)法及英国药品和保健
          产品管理局(MHRA)综合标准法(以下简称“MHRA”法)进行风险信号挖掘。结果  特许药品监测系统收到的72份氟轻松玻璃体
          植入剂ADR/ADE报告中,患者男女比例为1∶1.4,患者年龄主要分布在18~64岁;ADR/ADE共累及5个系统器官,眼器官疾病占
          比87.7%;新的一般的ADR报告9份(占12.5%),严重的ADR报告4份(占5.6%);ROR法及MHRA法均挖掘出白内障、青光眼、高
          眼压3个风险信号。FAERS数据库收到的244份报告中,患者男女比例为1∶1.5;ADR/ADE共累及10个系统器官,各类损伤、中毒
          及操作并发症占46.1%,产品问题占32.0%;严重的ADR报告20份(占8.2%);ROR法及MHRA法均挖掘出植入并发症、给药系统
          问题等19个风险信号。结论  临床使用氟轻松玻璃体植入剂时除了关注高眼压、白内障、青光眼等眼部ADR/ADE外,也应警惕产
          品质量及不合理使用方面的ADE所引发的潜在风险。
          关键词  氟轻松玻璃体植入剂;葡萄膜炎;不良反应;不良事件;风险信号;报告比值比;英国药品和保健产品管理局


          Risk signals mining for Fluocinolone acetonide intravitreal implants based on Hainan Province Franchised
          Drug Monitoring System and FAERS
          MIAO Huiqing ,LIN Kai ,YAO Minghong ,LIN Lijun(1.  Center  for  Pharmacovigilance  of  Hainan  Province,
                                2
                       1
                                                3
                                                           4
          Haikou 570216, China;2. Hainan Drug and Medical Device Evaluation Service Center, Haikou 570216, China;
          3. China Evidence-Based Medicine Center, West China Hospital, Sichuan University, Chengdu 610041, China;
          4. Center for Pharmacovigilance of Haikou, Haikou 570100, China)
          ABSTRACT   OBJECTIVE  To  explore  the  risk  signals  of  Fluocinolone  acetonide  intravitreal  implants  and  promote  safe  and

          rational  drug  use  for  patients.  METHODS  Based  on  the  data  from  the  Hainan  Province  Franchised  Drug  Adverse  Reaction
          Monitoring Subsystem (hereinafter referred to as the “Franchised Drug Monitoring System”) and the FDA Adverse Event Reporting
          System (FAERS),  the  adverse  drug  reaction (ADR)/adverse  drug  event (ADE)  reports  of  Fluocinolone  acetonide  intravitreal
          implants were coded by using system organ classification and preferred terminology, and relevant patient information was collected.
          Risk signal mining was carried out by using the reporting odds ratio (ROR) method and the comprehensive standards method of the
          UK  Medicines  and  Healthcare  Products  Regulatory Agency (hereinafter  referred  to  as  the “MHRA  method”).  RESULTS  Among
          the 72 reports of Fluocinolone acetonide intravitreal implants received by the Franchised Drug Monitoring System, the ratio of male
          to female was 1∶1.4, the patient’s age was mainly distributed between 18 and 64 years old; ADR/ADE affected 5 systemic organs,
          with  eye  organ  diseases  accounting  for  87.7%;  among  them,  there  were  9  new  and  general  ADR  reports (12.5%)  and  4  severe
          ADR  reports (5.6%);  ROR  method  and  MHRA  method  both  identified  three  risk  signals:  cataracts,  glaucoma,  and  high
                                                             intraocular  pressure.  Among  the  244  reports  received  by  the
             Δ 基金项目 海南省自然科学基金项目(No.821MS0818)                FAERS database, the ratio of male to female was 1∶1.5; ADR/
             *第一作者 高级工程师。研究方向:药物警戒、真实世界数据。
                                                             ADE  damage  affected  10  systemic  organs,  with  46.1%
          E-mail:895607221@qq.com
             # 通信作者 正高级工程师。研究方向:药物警戒、真实世界数据。                 suffering  from  various  injuries,  poisoning,  and  operational
          E-mail:439856605@qq.com                            complications,  and  32.0%  suffering  from  product  problems;


          中国药房  2024年第35卷第12期                                              China Pharmacy  2024 Vol. 35  No. 12    · 1505 ·
   98   99   100   101   102   103   104   105   106   107   108